Considerations for the Introduction of TLD in National Programs: PEPFAR Guidance on Developing Clinical and Programmatic Recommendations

This considerations document is intended to inform clinical and programmatic decision-making as country programs introduce TLD.

Download Resource

This document supports country program managers to develop clinical guidance and implementation plans for the introduction of the fixed-dose combination tablet of tenofovir, lamivudine and dolutegravir (TLD). It combines summaries of current normative guidance, available evidence, and programmatic considerations to inform the practical decisions that countries will need to make to develop comprehensive guidance on the use of TLD.

View All Resources

View All Resources

ARV Information

Toolkit & Guidance documents